We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+5.67%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$4.78B
AUM Growth
–
Cap. Flow
+$4.65B
Cap. Flow
% of AUM
97.21%
Top 10 Holdings %
Top 10 Hldgs %
14.27%
Holding
616
New
605
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$91.9M |
| 2 |
CELG
Celgene Corp
CELG
|
+$79.7M |
| 3 |
Apple
AAPL
|
+$78.2M |
| 4 |
Qualcomm
QCOM
|
+$73.5M |
| 5 |
Amgen
AMGN
|
+$71.4M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.38% |
| 2 | Financials | 14.02% |
| 3 | Technology | 12.7% |
| 4 | Industrials | 8.01% |
| 5 | Energy | 6.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
American Tower
AMT
$77.7B
| $2.43M | 0.05% |
+24,593
| New | +$2.42M |
|
327
Enbridge
ENB
$124B
| $2.38M | 0.05% |
+46,155
| New | +$2.17M |
|
|
SAGE
328
DELISTED
Sage Therapeutics
SAGE
| $2.38M | 0.05% |
+65,000
| New | +$2.42M |
|
329
Booking.com
BKNG
$138B
| $2.37M | 0.05% |
+51,900
| New | +$2.34M |
|
330
Simon Property Group
SPG
$74.5B
| $2.35M | 0.05% |
+12,895
| New | +$2.29M |
|
331
Zoetis
ZTS
$31.6B
| $2.34M | 0.05% |
+54,466
| New | +$2.21M |
|
|
KTWO
332
DELISTED
K2M Group Holdings, Inc
KTWO
| $2.3M | 0.05% |
+110,000
| New | +$1.9M |
|
333
Scotiabank
BNS
$106B
| $2.29M | 0.05% |
+42,327
| New | +$2.38M |
|
|
TLM
334
DELISTED
TALISMAN ENERGY INC
TLM
| $2.29M | 0.05% |
+290,901
| New | +$1.83M |
|
|
SGEN
335
DELISTED
Seagen Inc. Common Stock
SGEN
| $2.25M | 0.05% |
+70,000
| New | +$2.44M |
|
|
WBA
336
DELISTED
Walgreens Boots Alliance
WBA
| $2.25M | 0.05% |
+29,505
| New | +$1.97M |
|
|
ESPR
337
DELISTED
Esperion Therapeutics
ESPR
| $2.22M | 0.05% |
+55,000
| New | +$1.68M |
|
338
Morgan Stanley
MS
$337B
| $2.2M | 0.05% |
+56,728
| New | +$2.02M |
|
|
TTPH
339
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $2.18M | 0.05% |
+2,750
| New | +$1.48M |
|
340
Geron
GERN
$911M
| $2.18M | 0.05% |
+670,000
| New | +$1.85M |
|
|
XLRN
341
DELISTED
Acceleron Pharma
XLRN
| $2.14M | 0.04% |
+55,000
| New | +$1.92M |
|
342
Range Resources
RRC
$9.11B
| $2.11M | 0.04% |
+39,465
| New | +$2.55M |
|
|
MDCO
343
DELISTED
Medicines Co
MDCO
| $2.08M | 0.04% |
+75,000
| New | +$1.86M |
|
344
Costco
COST
$415B
| $2M | 0.04% |
+14,085
| New | +$1.91M |
|
345
Kinder Morgan
KMI
$73.1B
| $1.99M | 0.04% |
+47,009
| New | +$1.85M |
|
|
OMED
346
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $1.96M | 0.04% |
+90,000
| New | +$1.84M |
|
347
Align Technology
ALGN
$12B
| $1.96M | 0.04% |
+35,000
| New | +$1.85M |
|
|
BDSI
348
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $1.92M | 0.04% |
+160,000
| New | +$2.43M |
|
|
LITS
349
Lite Strategy Inc
LITS
$33.6M
| $1.91M | 0.04% |
+22,365
| New | +$2.94M |
|
350
CMS Energy
CMS
$23.1B
| $1.91M | 0.04% |
+54,878
| New | +$1.79M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q4 2014 Portfolio in Review
Q4 2014 is the first quarter with a 13F filing on record for Candriam SCA, which disclosed 616 positions worth $4.78B. Its ten largest holdings account for 14% of the portfolio.
Its largest position is Gilead Sciences: 888,125 shares worth $83.7M.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, followed by Financials and Technology.
- Candriam SCA's largest Q4 2014 buy was Gilead Sciences: 888,125 shares worth $83.7M.
- Candriam SCA's ten largest holdings make up 14% of its $4.78B portfolio in Q4 2014.
- Candriam SCA disclosed 616 positions in Q4 2014, its first 13F filing on record.
Based on Candriam SCA's 13F filing for Q4 2014, filed 26 Mar 2015.